A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Sponsor: Boston Children's Hospital
A PHASE1 clinical study on Malignant Glioma and Recurrent Ependymoma, this trial is completed. The trial is conducted by Boston Children's Hospital and has accumulated 12 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Sep 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 7 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE1
-
Aug 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Children's Hospital
- Candel Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .